Drug intelligence / Profile preview

CBD100

Development stage
Preclinical
Lead developer
Futura Medical
Modality
Small Molecules
Administration
Transdermal, Topical
01

Overview

CBD100 is a transdermal gel formulation of cannabidiol (CBD) developed through a joint venture between CBDerma Technology and Futura Medical. The product utilizes Futura Medical's proprietary DermaSys® drug delivery technology, which is designed to enhance skin penetration and provide rapid, targeted local delivery of the active pharmaceutical ingredient. Cannabidiol is a non-psychoactive, non-addictive small molecule derived from the cannabis plant. CBD100 is intended for a variety of applications, including the treatment of dermal conditions, topical pain relief, and cosmeceutical uses. As of 2021, the developers were conducting stability studies and exploring commercialization options for the formulation.

Other names
CBD100 DermaSys gelCBD-100 DermaSys gelCBD 100 DermaSys gelcannabidiol transdermal gel
02

Targets

HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))CNR1 (Cannabinoid receptor 1)CNR2 (Cannabinoid receptor type 2)GPR55 (G protein-coupled receptor 55)TRPV1 (Transient receptor potential cation channel subfamily V member 1)

Beyond the preview

Go deeper on CBD100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CBD100.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call